The Galenic, Analytical and Regulatory Development as well as the approval process by Infarmed and the Regulatory Authorities of those countries, including clinical trials proving the Bio equivalence of the product, represented 3 years of work and an investment of several hundred thousand Euros.
Lymecycline, an antibiotic of the Tetracycline family and whose main indication is the treatment of Acne, represents for Atral the entry into 4 of the most demanding European markets, England, Ireland, Denmark and Sweden, with the company expecting the export of this product to contribute in the future with 10% to 12% for its overall revenues.
Atral is licensing Lymecycline to other markets across continents and plans to have the product marketed in about 10 countries by the end of 2019.